N/A
N=270
Ultrasound Guided Catheter Length Survivability
Catheter Complications
Bottom Line
View on ClinicalTrials.gov: NCT03655106 ↗Enrolled (actual)
270
Serious AEs
0.0%
Results posted
Mar 2020
Primary outcome: Primary: Duration of IV Survival — 92; 136 hours
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Standard Long IV 4.78 cm 20 g catheter (Device); Ultra-Long IV 6.35 cm 20 g catheter (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Corewell Health East
- Primary completion
- Jul 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Duration of IV Survival |
92; 136 | — |
| SECONDARY Thrombosis |
0; 0 | — |
| SECONDARY Infection |
0; 0 | — |
Summary
In patients with difficult IV access, ultrasound-guided catheter insertion is a preferred technique. However, many peripheral catheters fail and must be replaced, adding extra pain and difficulty for the patient, and requiring more healthcare provider time to maintain. In preliminary studies, we determined that catheters which extend further into the vein have a smaller failure rate. This study will compare two lengths of catheters to see if the longer catheters have better survival in a population of patients who have difficult IV access. Patients will be randomized to receive a standard length or extra-long venous catheter, which will be monitored daily for functionality during the patient's hospital course.
Eligibility Criteria
Inclusion Criteria
Age 18 years or older
Self-reported difficult IV Access Patient and any one of the following:
- Greater than 2 sticks in previous admission/hospital encounter
- History of rescue vascular access device (such as US-guided IV, PICC line, midline, or CVC)
- End-stage renal disease on dialysis
- History of IV Drug Use
- History of Sickle Cell Disease
Exclusion Criteria
Age under 18 years old
- Voluntary withdrawal or refusal to participate
- Previous enrollment into the study
Data sourced from ClinicalTrials.gov (NCT03655106). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.